Shareholder Information

Shares Issued

As at 6 March 2024, the number of shares in issue was 1,341,815,988.

 

Significant Shareholders

As at 6 March 2024


None known at present time except for Director shareholdings (see below).

 

Director Shareholdings

As at 6 March 2024

Director Number Ordinary
Shares %
Alexis Sandler 75,090,685 5.60
Dr Vladislav Sandler 41,544,677 3.10
Peter Redmond 5,596,270 0.42

 

Shares Not In Public Hands

Insofar as it is aware, as at 6 March 2024, 14.25% of the Company’s securities were not in public hands.

 

UK City Code On Takeovers And Mergers

The Company is subject to the provisions of the City Code on Takeovers and Mergers.

 

Shareholder Circulars

Annual and Half Year Reports, together with historical general meeting notices, blank proxy voting forms, and other shareholder circulars, may be found here: Annual and Half Year Reports.

Most recent shareholder circular:

2 June 2023 Notice of Annual General Meeting to be held on 30 June 2023

 

Other Exchanges And Trading Platforms

Hemogenyx Pharmaceuticals plc has not applied or agreed to have any of it securities admitted or traded on any other exchanges or trading platforms.